Study Results from National Center for Nanoscience and Technology Provide New Insights into Proteomics (Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation)

Citation metadata

Date: Sept. 3, 2016
Publisher: NewsRX LLC
Document Type: Report
Length: 414 words

Document controls

Main content

Full Text: 

2016 SEP 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Proteomics are discussed in a new report. According to news originating from Beijing, People's Republic of China, by NewsRx correspondents, research stated, "Peptide therapeutics hold great promise for the treatment of cancer due to low toxicity, high specificity, and ease of synthesis and modification. However, the unfavorable pharmacokinetic parameters strictly limit their therapeutic efficacy and clinical translation."

Our news journalists obtained a quote from the research from National Center for Nanoscience and Technology, "Here, we tailor-designed an amphiphilic chimeric peptide through conjugation of functional 3-diethylaminopropyl isothiocyanate (DEAP) molecules to a short antitumor peptide, C16Y. The ultimate DEAP-C16Y peptides self-assembled into spherical nanostructures at physiologic conditions, which dissociated to release individual peptide molecules in weakly acidic tumors. DEAP-C16Y peptides showed negligible cytotoxicity but impaired vascular endothelial cell migration and tubule formation by inactivation of the focal adhesion kinase and PI3K-Akt pathways, as well as tumor cell invasion by decreasing invadopodia formation. Compared with C16Y, the systemically administered DEAP-C16Y nanostructures exhibited superior stability, thereby allowing prolonged treatment interval and resulting in significant decreases in microvessel density, tumor growth, and distant metastasis formation in orthotopic mammary tumor models. Through encapsulation of hydrophobic doxorubicin, DEAP-C16Y nanostructure served as a smart carrier to achieve targeted drug delivery and combination therapy."

According to the news editors, the research concluded: "Our study, for the first time, demonstrates that a simple nanoformulation using a functional antitumor peptide as the building block can show innate antitumor activity and also provide a nanoplatform for combination therapy, opening a new avenue for the design of antitumor nanotherapeutics."

For more information on this research see: Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation. Molecular Cancer Therapeutics, 2015;14(10):2390-400. (American Association for Cancer Research -; Molecular Cancer Therapeutics -

The news correspondents report that additional information may be obtained from Y. Ding, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, People's Republic of China. Additional authors for this research include T. Ji, Y. Zhao, Y. Zhang, X. Zhao, R. Zhao, J. Lang, X. Zhao, J. Shi, S. Sukumar and G. Nie.

Keywords for this news article include: Asia, Beijing, Therapy, Peptides, Proteins, Proteomics, Nanostructural, Nanostructures, Nanotechnology, Emerging Technologies, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

Source Citation

Source Citation   

Gale Document Number: GALE|A461805606